The bioprinting specialist Organovo entered the New York Stock Exchange today. Last thursday, July 11, the ONVO shares began trading on the NYSE after qualifying as an NYSE MKT listing company. The stock is currently up another 14% at about $6.90.
“Organovo is proud to ring the opening bell on behalf of our employees, investors and all of our supporters, in recognition of our recent uplisting to the New York Stock Exchange. This milestone is another important step forward for the company in our mission to advance the impact of 3D bioprinting in changing the shape of medical research and practice,” said Keith Murphy, president and chief executive officer of Organovo Holdings, Inc. “We found NYSE to have made an unparalleled commitment to providing a fertile platform for growth to early stage biotechnology companies, and we look forward to a great future on the exchange.”
“As Scientific Founder of Organovo I am deeply moved by this latest success of the company,” said Professor Gabor Forgacs of the University of Missouri-Columbia and Clarkson University. “For a scientist, watching the progress of one’s technology represents the ultimate dream come true, and it is rewarding to see the numerous nights spent in the academic lab, combined with the many long hours devoted by Organovo’s team, creating realistic hope for many patients for improved quality of life.”
Organovo ringing the NSYE opening bell